Thelansis

Primary Hyperoxaluria Type 1 (PH1) Market Outlook Thelansis’s “Primary Hyperoxaluria Type 1 (PH1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria Type 1 (PH1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Hyperoxaluria Type 1 (PH1) Overview Primary hyperoxaluria type 1 (PH1) is a rare, autosomal recessive metabolic disorder caused by  AGXT  gene mutations, which deplete hepatic peroxisomal alanine-glyoxylate aminotransferase. This deficiency halts glyoxylate detoxification, driving massive hepatic oxalate overproduction. When this burden overwhelms renal excretion, calcium oxalate ...

Primary Hyperoxaluria Type 1 (PH1) Market Outlook Thelansis’s “Primary Hyperoxaluria Type 1 (PH1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria Type 1 (PH1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the...

Primary Hyperoxaluria Type 1 (PH1) Market Outlook Thelansis’s “Primary Hyperoxaluria Type 1 (PH1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria Type 1 (PH1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

  Primary Hyperoxaluria Type 1 (PH1) Market Outlook Thelansis’s “Primary Hyperoxaluria Type 1 (PH1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria Type 1 (PH1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Hyperoxaluria Type 1 (PH1) Overview Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutations in the AGXT gene, inherited in an autosomal recessive manner. This condition inflicts irreversible harm on the kidneys and other vital organs, carrying the potential for life-threatening consequences. PH1 results from a deficiency of the liver peroxisomal enzyme called alanine: ...

 Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutations in the AGXT gene, inherited in an autosomal recessive manner. This condition inflicts irreversible harm on the kidneys and other vital organs, carrying the potential for life-threatening consequences. PH1 results from a deficiency of the liver peroxisomal enzyme called alanine: glyoxylate-aminotransferase (AGT). AGT plays a crucial role in converting glyoxylate into glycine. Individuals affected by PH1 are susceptible to recurrent nephrolithiasis, which is the deposition of calcium oxalate in the renal pelvis and urinary tract, nephrocalcinosis, characterized by calcium oxalate buildup in the renal parenchyma, and end-stage renal disease (ESRD). Roughly 10% of those with PH1 experience symptoms during infancy or early childhood, including nephrocalcinosis, sometimes nephrolithiasis, and growth issues due to renal failure. Most individuals with PH1 are diagnosed during childhood or early adolescence, o...